Developer docs
API playgroundTry for free, no card

Search company profiles

NewLimit

Full company profile

uuid00005oy

Namestring
NewLimit
Legal namestring
NewLimit, Inc.
Websiteurl
newlimit.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

NewLimit is a preclinical-stage biotechnology company founded in 2022 and headquartered in South San Francisco, California, developing epigenetic reprogramming medicines to restore youthful function in old cells with the goal of extending human healthspan. The company is built around a single integrated technology platform called the Discovery Engine, which combines the Ambrosia AI system for in silico payload design, the RESTORE-seq high-throughput molecular screening system that pairs DNA-barcoded transcription factors with single-cell epigenetic profiling, lipid nanoparticle (LNP)-formulated mRNA delivery of transcription factors in vivo, and humanized liver mouse models for preclinical validation. Per company disclosures, the Discovery Engine has scaled to test over 1,000 times more reprogramming payloads than the rest of the field combined and follows a reported biological scaling law for discovery rate.

The platform supports three therapeutic programs: a lead Metabolism program targeting hepatocytes (liver) with an initial indication in alcohol-related and fatty liver disease, an Immunology program restoring youthful function in aged T cells, and a Vascular program focused on rejuvenating endothelial cells in the kidney. The lead preclinical candidate for the liver was achieved three years after founding (versus a five-year projection), and the company plans to submit a clinical trial application in 2027 with first-in-human Phase I trials planned for the same year. The company also plans to open its own clinical research clinic in 2027.

NewLimit is pre-revenue with no approved products. The current go-to-market is community-led, centered on a Substack blog with over 4,000 subscribers publishing bi-monthly progress updates, a corporate website, an active Twitter account, and extensive earned media in Forbes, Stat News, TechCrunch, Endpoints, and FierceBiotech. Future commercial motion is expected to combine direct sales to hospitals and health systems, pharmaceutical partnerships and licensing (signaled by Eli Lilly's equity investment and former Lilly CSO Matthew Breyer's presence on the Scientific Advisory Board), and potential platform licensing of the Discovery Engine and Ambrosia AI. As of the June 2026 Series C, the company had raised approximately $650 million+ across all rounds at a roughly $3.1 billion post-money valuation.

Short descriptiontext

NewLimit is a preclinical-stage biotechnology company developing AI-driven epigenetic reprogramming medicines to restore youthful function in old cells. Its Discovery Engine supports three therapeutic programs in liver, immune, and vascular disease, with first human trials planned for 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epigenetic reprogramming, longevity biotechnology, AI drug discovery, mRNA therapeutics delivery, age-related disease therapy
Industry3 codes
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Epigenetic Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Not yet generating revenue (preclinical)
TypeLicensing Royalties
Description

NewLimit is a preclinical-stage biotechnology company with no approved products and no current revenue. The company plans to initiate its first human clinical trial in 2027. Future revenue streams are expected to include direct sales of approved reprogramming medicines to hospitals and health systems, milestone payments and royalties from pharmaceutical collaborations (already signaled by the Eli Lilly investment), and potential platform licensing of the Discovery Engine and Ambrosia AI system.

blog.newlimit.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NewLimit is developing epigenetic reprogramming medicines that restore youthful function to old cells using transcription factor payloads delivered via lipid nanoparticle (LNP)-formulated mRNA. The company's lead program targets hepatocytes to treat alcohol-related and fatty liver disease, with parallel programs in T cell rejuvenation (immunology) and endothelial cell rejuvenation (vascular, initially kidney). All discovery is powered by an integrated Discovery Engine combining the proprietary Ambrosia AI system, RESTORE-seq high-throughput functional genomics screening, and single-cell epigenetic profiling.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 8X improvement in hepatocyte specificity over starting TF sequence
+9 more records
Product overview1 text field

NewLimit operates a single unified R&D platform — the Discovery Engine — that combines proprietary AI (Ambrosia) with high-throughput molecular screening (RESTORE-seq) to discover epigenetic reprogramming medicines. The platform feeds three distinct therapeutic programs: (1) the lead Metabolism program targeting hepatocytes to treat liver disease and preserve metabolic health, (2) the Immunology program restoring youthful function in T cells for inflammatory/autoimmune conditions, and (3) the Vascular program rejuvenating endothelial cells (initially in the kidney) for kidney and cardiovascular disease. The Metabolism program is the most advanced, with a lead preclinical candidate advancing to manufacturing and planned first-in-human clinical trials in 2027. The Vascular and Immunology programs represent parallel expansion of the same reprogramming platform to additional cell types and disease areas.

Product and service3 records
1Metabolism Program (Liver/Hepatocyte Reprogramming)
CategoryTherapeutic program
Description

NewLimit's lead therapeutic program developing reprogramming medicines to restore youthful function in old hepatocytes (liver cells), initially targeting alcohol-related liver disease and fatty liver disease, with the broader goal of preserving metabolic health. Aimed at patients with liver disease and clinicians (hepatologists) treating age-related metabolic decline.

2Immunology Program (T Cell Reprogramming)
CategoryTherapeutic program
Description

Therapeutic program working to restore specificity and a normal immunological state in old T cells, initially focused on inflammatory diseases of aging, with potential applications across inflammatory, infectious, and neoplastic diseases including rheumatoid arthritis. Aimed at patients with age-related immune dysfunction and immunology specialists.

3Vascular Program (Endothelial Cell Reprogramming)
CategoryTherapeutic program
Description

Therapeutic program developing reprogramming medicines to rescue endothelial cell function, initially focused on rejuvenating endothelial cells in the kidney to reverse the course of kidney disease and preserve renal function, with future applications in cardiovascular, metabolic, and cognitive health via vascular rejuvenation. Aimed at patients with kidney and vascular disease.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor pursuing cellular rejuvenation programming to restore cell health and reverse disease, with a $3B raise in 2022 making it the most capitalized pure-play reprogramming company. Operates in the same epigenetic reprogramming space targeting biological rejuvenation.

TypeDirect peer
Description

Sam Altman-backed longevity biotech that raised $1B+ to develop cellular reprogramming, autophagy, and plasma-inspired therapies. Directly comparable to NewLimit on partial reprogramming modality and longevity disease focus.

TypeDirect peer
Description

Alphabet/Google-backed longevity company focused on cellular reprogramming and aging biology. Jacob Kimmel (NewLimit CEO) previously led a reprogramming lab at Calico, making this a direct technical peer with effectively unlimited capital.

TypeDirect peer
Description

Pure-play longevity biotech developing gene therapy and cellular reprogramming approaches to treat age-related diseases. Directly comparable focus on partial reprogramming and age-driven disease indications.

5Turn Biotechnologies
TypeDirect peer
Description

Epigenetic reprogramming company developing mRNA-based therapies to temporarily express Yamanaka factors and restore youthful cell function. Direct competitor in the same modality targeting age-related disease indications.

6AgeX Therapeutics
TypeDirect peer
Description

Biotechnology company developing therapeutics focused on biological aging and senescence, with stem cell and cellular regeneration programs. Comparable longevity/biogerontology focus with overlapping epigenetic and cell-rejuvenation themes.

TypeDirect peer
Description

Clinical-stage longevity biotech developing senolytic medicines that selectively eliminate senescent cells to treat age-related diseases. Overlapping target disease areas (liver, ophthalmology) and longevity therapeutic modality, though different mechanism.

TypeEmerging player
Description

AI-driven drug discovery company combining generative AI with target identification for aging and age-related diseases, including fibrosis. Shares NewLimit's AI-driven platform approach but focuses more broadly on traditional small-molecule discovery.

TypeEmerging player
Description

George Church-cofounded biotech using gene therapy to reverse aging and treat age-related diseases in dogs and humans. Comparable focus on age-related disease reversal but via gene therapy rather than epigenetic reprogramming.

TypeRegional player
Description

Clinical-stage gene therapy company where NewLimit's Head of Translation Melissa Calton previously served as VP of Early-Stage Product Development. Comparable preclinical-to-clinical translation of novel genetic medicines, though focused on AAV gene therapy rather than reprogramming.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NewLimit

Epigenetic Therapeuticsnewlimit.com

NewLimit is a preclinical-stage biotechnology company developing AI-driven epigenetic reprogramming medicines to restore youthful function in old cells. Its Discovery Engine supports three therapeutic programs in liver, immune, and vascular disease, with first human trials planned for 2027.

What NewLimit does

NewLimit is a preclinical-stage biotechnology company founded in 2022 and headquartered in South San Francisco, California, developing epigenetic reprogramming medicines to restore youthful function in old cells with the goal of extending human healthspan. The company is built around a single integrated technology platform called the Discovery Engine, which combines the Ambrosia AI system for in silico payload design, the RESTORE-seq high-throughput molecular screening system that pairs DNA-barcoded transcription factors with single-cell epigenetic profiling, lipid nanoparticle (LNP)-formulated mRNA delivery of transcription factors in vivo, and humanized liver mouse models for preclinical validation. Per company disclosures, the Discovery Engine has scaled to test over 1,000 times more reprogramming payloads than the rest of the field combined and follows a reported biological scaling law for discovery rate.

The platform supports three therapeutic programs: a lead Metabolism program targeting hepatocytes (liver) with an initial indication in alcohol-related and fatty liver disease, an Immunology program restoring youthful function in aged T cells, and a Vascular program focused on rejuvenating endothelial cells in the kidney. The lead preclinical candidate for the liver was achieved three years after founding (versus a five-year projection), and the company plans to submit a clinical trial application in 2027 with first-in-human Phase I trials planned for the same year. The company also plans to open its own clinical research clinic in 2027.

NewLimit is pre-revenue with no approved products. The current go-to-market is community-led, centered on a Substack blog with over 4,000 subscribers publishing bi-monthly progress updates, a corporate website, an active Twitter account, and extensive earned media in Forbes, Stat News, TechCrunch, Endpoints, and FierceBiotech. Future commercial motion is expected to combine direct sales to hospitals and health systems, pharmaceutical partnerships and licensing (signaled by Eli Lilly's equity investment and former Lilly CSO Matthew Breyer's presence on the Scientific Advisory Board), and potential platform licensing of the Discovery Engine and Ambrosia AI. As of the June 2026 Series C, the company had raised approximately $650 million+ across all rounds at a roughly $3.1 billion post-money valuation.

NewLimit firmographics

Firmographics
Name
NewLimit
Legal name
NewLimit, Inc.
Website
https://newlimit.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
NewLimit is a preclinical-stage biotechnology company developing AI-driven epigenetic reprogramming medicines to restore youthful function in old cells. Its Discovery Engine supports three therapeutic programs in liver, immune, and vascular disease, with first human trials planned for 2027.
Ownership category
akta.pro rank

Where NewLimit is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NewLimit business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Not yet generating revenue (preclinical): NewLimit is a preclinical-stage biotechnology company with no approved products and no current revenue. The company plans to initiate its first human clinical trial in 2027. Future revenue streams are expected to include direct sales of approved reprogramming medicines to hospitals and health systems, milestone payments and royalties from pharmaceutical collaborations (already signaled by the Eli Lilly investment), and potential platform licensing of the Discovery Engine and Ambrosia AI system.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

NewLimit product offering

Product offering

Core offering

NewLimit is developing epigenetic reprogramming medicines that restore youthful function to old cells using transcription factor payloads delivered via lipid nanoparticle (LNP)-formulated mRNA. The company's lead program targets hepatocytes to treat alcohol-related and fatty liver disease, with parallel programs in T cell rejuvenation (immunology) and endothelial cell rejuvenation (vascular, initially kidney). All discovery is powered by an integrated Discovery Engine combining the proprietary Ambrosia AI system, RESTORE-seq high-throughput functional genomics screening, and single-cell epigenetic profiling.

Product overview

NewLimit operates a single unified R&D platform — the Discovery Engine — that combines proprietary AI (Ambrosia) with high-throughput molecular screening (RESTORE-seq) to discover epigenetic reprogramming medicines. The platform feeds three distinct therapeutic programs: (1) the lead Metabolism program targeting hepatocytes to treat liver disease and preserve metabolic health, (2) the Immunology program restoring youthful function in T cells for inflammatory/autoimmune conditions, and (3) the Vascular program rejuvenating endothelial cells (initially in the kidney) for kidney and cardiovascular disease. The Metabolism program is the most advanced, with a lead preclinical candidate advancing to manufacturing and planned first-in-human clinical trials in 2027. The Vascular and Immunology programs represent parallel expansion of the same reprogramming platform to additional cell types and disease areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • Metabolism Program (Liver/Hepatocyte Reprogramming) NewLimit's lead therapeutic program developing reprogramming medicines to restore youthful function in old hepatocytes (liver cells), initially targeting alcohol-related liver disease and fatty liver disease, with the broader goal of preserving metabolic health. Aimed at patients with liver disease and clinicians (hepatologists) treating age-related metabolic decline.
  • Immunology Program (T Cell Reprogramming) Therapeutic program working to restore specificity and a normal immunological state in old T cells, initially focused on inflammatory diseases of aging, with potential applications across inflammatory, infectious, and neoplastic diseases including rheumatoid arthritis. Aimed at patients with age-related immune dysfunction and immunology specialists.
  • Vascular Program (Endothelial Cell Reprogramming) Therapeutic program developing reprogramming medicines to rescue endothelial cell function, initially focused on rejuvenating endothelial cells in the kidney to reverse the course of kidney disease and preserve renal function, with future applications in cardiovascular, metabolic, and cognitive health via vascular rejuvenation. Aimed at patients with kidney and vascular disease.

Quantifiable outcome

  • 8X improvement in hepatocyte specificity over starting TF sequence
  • +9 more outcomes

Companies that use NewLimit

Customer profile

Segments3 records

Ideal customer profiles3 records

NewLimit technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature7 records

NewLimit partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

NewLimit competitors and assessment

Company assessment

Direct peers

  • Altos Labs: Direct competitor pursuing cellular rejuvenation programming to restore cell health and reverse disease, with a $3B raise in 2022 making it the most capitalized pure-play reprogramming company. Operates in the same epigenetic reprogramming space targeting biological rejuvenation.
  • Retro Biosciences: Sam Altman-backed longevity biotech that raised $1B+ to develop cellular reprogramming, autophagy, and plasma-inspired therapies. Directly comparable to NewLimit on partial reprogramming modality and longevity disease focus.
  • Calico Life Sciences: Alphabet/Google-backed longevity company focused on cellular reprogramming and aging biology. Jacob Kimmel (NewLimit CEO) previously led a reprogramming lab at Calico, making this a direct technical peer with effectively unlimited capital.
  • Life Biosciences: Pure-play longevity biotech developing gene therapy and cellular reprogramming approaches to treat age-related diseases. Directly comparable focus on partial reprogramming and age-driven disease indications.
  • Turn Biotechnologies: Epigenetic reprogramming company developing mRNA-based therapies to temporarily express Yamanaka factors and restore youthful cell function. Direct competitor in the same modality targeting age-related disease indications.
  • AgeX Therapeutics: Biotechnology company developing therapeutics focused on biological aging and senescence, with stem cell and cellular regeneration programs. Comparable longevity/biogerontology focus with overlapping epigenetic and cell-rejuvenation themes.
  • Unity Biotechnology: Clinical-stage longevity biotech developing senolytic medicines that selectively eliminate senescent cells to treat age-related diseases. Overlapping target disease areas (liver, ophthalmology) and longevity therapeutic modality, though different mechanism.

Emerging players

  • Insilico Medicine: AI-driven drug discovery company combining generative AI with target identification for aging and age-related diseases, including fibrosis. Shares NewLimit's AI-driven platform approach but focuses more broadly on traditional small-molecule discovery.
  • Rejuvenate Bio: George Church-cofounded biotech using gene therapy to reverse aging and treat age-related diseases in dogs and humans. Comparable focus on age-related disease reversal but via gene therapy rather than epigenetic reprogramming.

Regional players

  • 4D Molecular Therapeutics: Clinical-stage gene therapy company where NewLimit's Head of Translation Melissa Calton previously served as VP of Early-Stage Product Development. Comparable preclinical-to-clinical translation of novel genetic medicines, though focused on AAV gene therapy rather than reprogramming.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

NewLimit social profiles

Digital presence

NewLimit financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NewLimit leadership team

Management profile

Number of profiles

Profiles6 records

NewLimit funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NewLimit M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NewLimit

What does NewLimit do?

NewLimit is developing epigenetic reprogramming medicines that restore youthful function to old cells using transcription factor payloads delivered via lipid nanoparticle (LNP)-formulated mRNA. The company's lead program targets hepatocytes to treat alcohol-related and fatty liver disease, with parallel programs in T cell rejuvenation (immunology) and endothelial cell rejuvenation (vascular, initially kidney). All discovery is powered by an integrated Discovery Engine combining the proprietary Ambrosia AI system, RESTORE-seq high-throughput functional genomics screening, and single-cell epigenetic profiling.

Is NewLimit a public or private company?

NewLimit is a private company. It is classified as venture growth investor backed and is currently operating.

When was NewLimit founded?

NewLimit was founded in 2022. It employs 51 to 100 people.

Where is NewLimit based?

NewLimit is headquartered in South San Francisco, United States, in the North America region.

How does NewLimit make money?

One revenue line is on record: not yet generating revenue (preclinical).

Who are NewLimit's main competitors?

Direct peers on record are Altos Labs, Retro Biosciences, Calico Life Sciences, Life Biosciences, Turn Biotechnologies, AgeX Therapeutics and Unity Biotechnology. Emerging players are Insilico Medicine and Rejuvenate Bio. 4D Molecular Therapeutics is listed as a regional player.

Does NewLimit have an API?

No public API is recorded for NewLimit.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialGlobal Longevity Biotech And Epigenetic Reprogramming Market Report 2026 Capture 12.9% CAGR As Altos Labs, Retro Biosciences, Newlimit And Life Biosciences Scale ReprogrammingThe global longevity biotech and epigenetic reprogramming market is projected to grow from $23.93 billion in 2025 to $27.11 billion in 2026, a 13.3% CAGR, reaching $44.05 billion by 2030. Life Biosciences received FDA clearance for its ER-100 therapy in January 2026, entering Phase 1 trials for optic neuropathies.PR NewswireAnti-Aging Drugs Market Poised for US$ 102.5 Bn Valuation by 2031, Growing at 6.25% CAGR, New Report by Wissen ResearchThe global anti-aging drugs market is projected to grow from USD 75.7 billion in 2026 to USD 102.5 billion by 2031, a CAGR of 6.25%. Growth is driven by an aging population, rising demand for minimally invasive treatments, and advancements in dermatological therapies. North America holds the largest regional share, while Asia-Pacific is the fastest-growing region.National GeographicAre We on the Brink of Ending Aging?In April 2026, Life Biosciences launched the first human clinical trial of ER-100, a cellular reprogramming therapy, injecting it into a glaucoma patient's eye at a Glendale, California facility as part of an FDA trial. The treatment, developed by Harvard Medical School's David Sinclair, aims to reverse aging by getting genes to turn back the clock on damaged cells, with the hope that it could eventually reverse aging altogether. The trial marks the latest development in a rapidly growing, billion-dollar anti-aging biotechnology race that includes Altos Labs, NewLimit, and Retro Biosciences, all pursuing similar cellular reprogramming approaches.BioSpace5 largest VC rounds of H1 2026In the first half of 2026, biopharma venture capital funding showed a "selective recovery," with $2.1 billion flowing to Isomorphic Labs—the second-largest biotech round ever—in May via a Series B led by investors betting on AI-driven drug discovery. Four other large raises followed: NewLimit ($435M Series C for epigenome reprogramming), Beeline Medicines ($426.3M Series A for immunology including assets from Bristol Myers Squibb), Parabilis Medicines ($305M Series F for a cancer peptide therapy, later followed by a record $670M IPO), and Corxel Pharmaceuticals ($287M Series D1 for a GLP-1 obesity drug). The overall trend reflects capital becoming more discerning, concentrating in later-stage, de-risked assets with near-term clinical catalysts while early-stage financing remains near its lowest annual count since before the pandemic.Labiotech.euThe biggest biotech funding rounds in June 2026June 2026 saw biotech companies raise a combined $4.724 billion across private and public funding, with NewLimit leading private rounds at $435 million series C and Parabilis Medicines setting a record with a $670 million IPO—the largest ever new stock sale for a venture-backed biotech. North American companies dominated fundraising with $2.696 billion from 19 rounds, while Europe raised $266.4 million and Asia-Pacific recorded no significant rounds. The strong month extended a streak of large biotech IPOs that has seen 12 startups secure over $4.1 billion combined in 2026.New Market PitchHow's the longevity market doing these days?The longevity market remains active but is shifting toward evidence-based investments, with capital concentrating in fewer, larger rounds tied to clinical development, scaled diagnostics, or measurable healthspan infrastructure rather than broad anti-aging branding. Recent milestones include NewLimit's $435 million Series C for epigenetic reprogramming, Life Biosciences dosing its first human patient with ER-100 for optic neuropathies, and Loyal advancing its dog-longevity drug LOY-002 through FDA review, while GLP-1s are establishing the strongest near-term bridge between mainstream medicine and longevity interventions.pharmaphorumNewLimit raises $435m for liver trials, and other financingsLongevity start-up NewLimit has raised $435 million in a Series C round led by Founders Fund to advance its liver age reprogramming therapy into human clinical trials next year, based on a breakthrough prototype medicine that reverses cell age in old human liver cells using lipid nanoparticle-delivered RNA coding for transcription factors. The financing brings forward the company's timeline, with the therapy designed to help livers heal faster after injury, avoid damage from dietary challenges, and accelerate recovery from alcohol consumption. Additional recent biotech financings include Ona Therapeutics' $86.6 million Series B for breast and colorectal cancer ADC candidates, IMU Biosciences' $53 million Series A for its immune biology dataset, Oak Hill Bio's $32.5 million Series A for an Angelman syndrome treatment, and Secretome Therapeutics' $30 million Series A for a Duchenne muscular dystrophy cardiomyopathy candidate.FightagingA Great Deal More Funding for the Development of Partial Reprogramming TherapiesNewLimit has raised $435 million in a Series C financing round led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital, and existing investors, to advance its epigenetic reprogramming therapies toward human clinical trials planned for next year. Retro Biosciences announced an initial close of its next financing round at a pre-money valuation of $1.8 billion, led by 4P Capital, as it progresses its clinical candidate RTR242 into first-in-human dosing. The article discusses how partial reprogramming has become the dominant hot area attracting biotech investment, while other aging research approaches like senolytics have seen comparatively less funding despite being earlier to the field.MIT Technology ReviewWhy “reprogramming” is the buzziest approach to reversing aging right nowLife Biosciences dosed its first volunteer with an experimental eye reprogramming treatment for glaucoma, aiming to regenerate healthy nerves. The approach, based on reprogramming cells to a younger state, has attracted billions in funding, with Sinclair planning to test an oral reprogramming drug in a XPrize competition.ForbesThe New Billionaire Bet Isn't AI — It's Longevity BiotechLongevity biotech companies raised approximately $3.74 billion across 49 financing events in the first quarter of 2026, up 56% year-over-year, as billionaire investors and pharmaceutical partners pour capital into the sector. Three converging forces are driving the surge: AI accelerating biological discovery, an estimated $236 billion to $300 billion in annual pharmaceutical revenue facing patent expiry by 2030, and a shift from wellness products toward therapies targeting the biological mechanisms of aging itself. Several companies, including NewLimit, HexemBio, and Colossal Biosciences, are advancing toward clinical validation and regulatory milestones, with HexemBio targeting first-in-human trials in 2027.